15d
GlobalData on MSNAnocca gains European authorisation for Phase I/II trial of pancreatic cancer drugIt will begin the evaluation with ANOC-001, Anocca’s lead product, which targets mutant KRAS glycine 12 mutated to valine ...
The most striking changes are depression of the branched chain amino acids (leucine, isoleucine and valine) and of lysine and tyrosine. Glycine and serine are elevated with glycine showing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results